Ovid Therapeutics Inc.

Contributing Author

Recent Articles by Ovid Therapeutics Inc.

9 hours	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results OVID GlobeNewswire
Oct-03	Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds OVID GlobeNewswire
Oct-03	Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile OVID GlobeNewswire
Aug-13	Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results OVID GlobeNewswire
Jul-23	Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference OVID GlobeNewswire
Jun-25	Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties OVID GlobeNewswire
Jun-05	Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 OVID GlobeNewswire
May-13	Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results OVID GlobeNewswire